Group News

Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future

Group News

2024-03-28

Viva Biotech will continue to advance the integrated CRO-CDMO strategy, aiming to establish comprehensive and comprehensive FIC drug development services to empower our clients.

More

Viva Biotech and Lonza Enter Licensing Agreement for Lonza's bYlok® Bispecific Pairing Technology

Group News

2024-03-20

Accessing this technology expands Viva Biotech's large molecule capabilities by supporting the design and production of bispecific antibodies.
AIxplorerBio published a research article in the J. Comput. Chem. on enhancing the efficiency of relative binding free energy calculation, with Dr. Yue Qian as the co-corresponding author.

Group News

2024-02-01

This is a highly productive collaboration between AIxplorerBio and Dr. Qian.
Viva Biotech was honored with

Group News

2024-01-15

Viva Biotech, utilizing multiple core technology platforms and one-stop service capabilities, empowers the development of the biopharmaceutical industry.
Unifying strength towards future: Viva Biotech's 2023 Milestone

Group News

2024-01-02

Farewell 2023, Meet 2024 - Together we head towards the next journey
Viva Insights: Using a Biophysical Technology Platform Makes Drug Development Faster and Optimizes Success

Group News

2021-12-14

The first Viva Live Broadcast was officially launched

1 2